Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial

  All patients n = 91 Control group n = 45 Intervention group n = 46
Newly diagnosed patients n (%) 25 (27) 13 (29) 12 (26)
Sex (female) n (%) 42 (46) 23 (51) 19 (41)
Age mean in years (sd) 62 (8) 63 (7) 62 (10)
Location of primary tumor: n (%)
 Pancreas 21 (23) 9 (20) 12 (26)
 Intestine 53 (58) 26 (58) 27 (59)
 Stomach/duodenum 3 (3) 2 (4) 1 (2)
 Colorectal 2 (3) 2 (4) 1 (2)
 Bronchopulmonal 1 (1) 1 (2) 0 (0)
 Appendix 1 (1) 1 (2) 0 (0)
 Unknown/other 9 (10) 4 (9) 5 (11)
Duration of disease in months: mean (SD) 41 (56) 33 (38) 50 (66)
Disease grade: n (%)
 1 57 (63) 27 (60) 30 (65)
 2 21 (23) 12 (27) 9 (20)
 Unknown 13 (14) 6 (13) 7 (15)
Marital state (Married) n (%) 75 (82) 34 (76) 41 (89)
Education (Polytechnic or university) n (%) 33 (37) 16 (36) 17 (38)
Internet use n (%)
 Daily 86 (96) 40 (91) 46 (100)
 For information about the disease 78 (87) 37 (82) 41 (89)
Treatment during study: n (%)
 Surgery 7 (8) 2 (4) 5 (11)
 PRRT 2 (2) 1 (2) 1 (2)
 SSA 64 (70) 32 (71) 32 (70)
 Systemic treatment other than SSA 17 (19) 9 (20) 8 (17)
Treatment before study: n (%)
 Surgery 52 (57) 26 (58) 26 (57)
 PRRT 2 (2) 0 (0) 2 (4)
 Radiotherapy 3 (3) 0 (0) 3 (6)
 SSA 65 (71) 32 (71) 33 (72)
 Systemic treatment other than SSA 23 (25) 12 (26) 11 (24)
 Other (RFA) 1 (1) 0 (0) 1 (2)
  1. n = number, PRRT = peptide receptor radionucleide therapy, RFA = radiofrequency ablation, SSA = somatostatin analogue